Kornimate/medical-research-clean huggingface dataset:
gender of anesthesiologist and time to labor epidural

Conditions: Labor Pain

Summary: the goal of this retrospective cohort study is to learn about wether the gender of the anesthetist affects time to epidural anesthesia (eda) for laboring women . the main questions it aims to answer are: 1. is there a gender difference in time to applying eda 2. what is the mean waiting for eda in laboring women in sweden participants (anesthesiologists) will be reviewed according to the time from when the midwife asks for eda to anesthesiologist register that it was in place

in certain hospital in sweden, a module on the most contemporary obstetric chart system in sweden allows for registration of time from request of eda to applied eda.time of request is made by the midwife and the tim of application is registered by the anesthesiologist. not all hospitals makes these registrations, thus only (i)hospitals having this module and (ii) hospitals willing to participate will be included.

Eligibility criteria:
inclusion criteria: * registered maternal request of epidural/spinal anesthesia anesthesia exclusion criteria: * not possible to determine gender by first name or by personal knowledge at participating site * duplicates * misregistered time-points of eda * not receiving eda (even if the initial intention was to apply eda) * uncertain which anesthesiologist that registered the time-point (more than one anesthesiologist involved in documentation or application) * none/ambiguous documentation of time-points

Keywords: labor pain epidural anesthesia time delay
does the enhanced rehabilitation programs facilitate the motor recovery after stroke?

Conditions: Poststroke/CVA Hemiparesis

Summary: study purpose this study will explore whether an additional rehabilitation program that focus on either upper or lower extremity training facilitate the recovery in upper or lower extremity. the recovery in both neurological status and motor functions will be explored.

design a single-blinded (assessor-blinded) randomized controlled trial. interventions the participants will be randomly assigned into two experiment groups (enhanced upper extremity program; and enhanced lower-extremity program). both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy. the enhanced upper extremity program group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity, while the enhanced lower-extremity program group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity. the participants receive 20-day training over a 4-week period. the additional program is designed to be specific to either upper-extremity or lower-extremity. accordingly, one group can be used as the control group of the other one.

Eligibility criteria:
inclusion criteria: 1. first-ever stroke with the onset 10-90 days prior to the enrollment 2. age: 20-80y 3. with a hemiplegic upper extremity with brunnstrom stage in i\~iv 4. able to understand simple orders (1-step orders, such as "raise your hand, touch your head....) 5. totally independent in activity of daily life before the onset of stroke exclusion criteria: 1. incompliance to the assessments or interventions due to unstable medical condition, abnormal cognition, or other conditions. 2. stroke of brainstem or cerebellum 3. had received craniotomy or ventriculoperitoneal shunting 4. needs of orthoses in walking before the onset of stroke 5. had had motor dysfunctions (eg, amputation, cerebral palsy, poliomyelitis or other neuromuscular diseases) before the stroke. 6. intracranial hemorrhage caused by artereovenous malformation, aneurysm, or tumor 7. able to walk independently for more than 50 meters.

Keywords: intensity rehabilitation
study evaluating a 13-valent pneumococcal conjugate vaccine administered to infants in taiwan

Conditions: Vaccines; Pneumococcal Conjugate Vaccine

Summary: the purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vpnc), relative to a 7-valent pneumococcal conjugate vaccine (7vpnc) when given concomitantly with routine vaccines in taiwan.


Eligibility criteria:
inclusion criteria: * healthy 2-month-old infants (42 to 98 days) * available for the entire study period (14 months) exclusion criteria: * previous vaccination with pneumococcal, diphtheria, tetanus, pertussis, polio, or hib vaccines * a previous anaphylactic reaction to any vaccine or vaccine-related component.

Keywords: prevention against pneumococcal disease
application of electrical neurostimulation transcutaneous in patients with primary dysmenorrhea.

Conditions: Primary Dysmenorrhea

Summary: the present study aims to verify the analgesic potential of a new methodological proposal for application for transcutaneous electrical nerve stimulation (tens interactive) using patients with primary dysmenorrhoea and compare it with placebo in a randomized double blind study with convenience sample.

the denouement will be the intensity of pain from visual analogue scale.

Eligibility criteria:
inclusion criteria: * primary dysmenorrhoea * moderate to severe pain exclusion criteria: * secondary dysmenorrhea * users of intrauterine device * cognitive impairment * failure to appear for treatment * pacemaker use * illicit drug use * epilepsy * skin problems * use of pain medication before the application of tens

Keywords: tens dysmenorrhea analgesia interactive
bone mineral changes around stemless and stemmed cementless femoral components

Conditions: Osteoarthritis of Hip

Summary: the purpose of this study is to determine if there is a difference in stress shielding and bone resorption of the proximal femur in two anatomical stem total hip designs.

stress shielding related bone resorption in the proximal femur after total hip arthroplasty continues to be a problem. the purpose of this prospective, randomized study was to evaluate which of the two anatomical stem designs achieved a more physiological load transfer by assessing bone mineral changes in the proximal femur after stem implantation.

Eligibility criteria:
inclusion criteria: * osteoarthritis of hip joint requiring total hip arthroplasty exclusion criteria: * neurologic disorders affecting motor function of lower extremity * foot and ankle disorders limiting ambulation of the patient * patients with bone metabolic disorders other than osteoporosis which prevents normal bone metabolism * multi-systemic inflammatory arthritis which debilitates patients other than hip joint.

Keywords: stress shielding bone mineral density stemless femoral component
diagnostic evaluation of patients with neuromuscular disease

Conditions: Neuromuscular Disease

Summary: the objectives of this protocol are to: 1) screen patients with various neuromuscular disorders and facilitate their entry into appropriate research protocols; 2) help resolve puzzling diagnostic neuromuscular problems and train fellows in the evaluation and treatment of neuromuscular diseases; and 3) provide follow up to patients who finished their participation in a previous study but they are not currently entered in another research protocol. no investigational treatments will be performed on this protocol but the tissues collected can be used for future research studies.

the objectives of this protocol are to: 1) screen patients with various neuromuscular disorders and facilitate their entry into appropriate research protocols; 2) help resolve puzzling diagnostic neuromuscular problems and train fellows in the evaluation and treatment of neuromuscular diseases; and 3) provide follow up to patients who finished their participation in a previous study but they are not currently entered in another research protocol. no investigational treatments will be performed on this protocol but the tissues collected can be used for future research studies.

Eligibility criteria:
* inclusion criteria: research patients will be studied under this protocol if they fulfill the following criteria: have an identifiable neuromuscular disorder that may be suitable for a specific current or future protocol; present a diagnostic puzzle in spite of the previously performed diagnostic work-up; have unusual manifestation of a more usual neuromuscular disease; have a disorder useful for teaching purposes. patients should be referred by a physician who will continue their care after our evaluation. a report of the patients' visit and tests, along with suggestions or recommendations will be sent to each referring physician. there is a wide spectrum of neuromuscular diseases to be studied, among them are: peripheral neuropathies, myopathies, dystrophies, myasthenia, stiff person syndrome, muscle cramps, myotonias, motor neuron diseases, post-polio syndrome, and certain demyelinating disorders affecting both the central and the peripheral nervous system.

Keywords: myopathy dystrophy neuropathy muscle weakness muscle cramps and pains neuromuscular disorders
efficiency of virtual reality exposure therapy in the management of body dysmorphic disorders in female adolescents with anorexia nervosa

Conditions: Anorexia Nervosa

Summary: anorexia nervosa is defined in dsm v as a quantitative and qualitative dietary restriction resulting in significant weight loss, intense fear of weight gain, altered weight and body shape perception (body dysmorphic disorder) and low self-esteem influenced by weight or body shape. body dysmorphic disorder is the most difficult symptom to manage in anorexia nervosa and its persistence is a factor associated with relapse. virtual reality exposure therapy has proven its effectiveness in the management of post-traumatic stress disorder in the military and is a widely used therapy. the effectiveness of this treatment using new technologies has not yet been studied for the treatment of body dysmorphic disorder in anorexia nervosa and is not used routinely. it could represent an interesting alternative to the physical approach in psychomotor therapy, traditionally offered to patients suffering from anorexia nervosa. it is important to evaluate the effectiveness of virtual reality exposure therapy in the management of body dysmorphic disorder in patients with anorexia nervosa by comparing these two care techniques.

the aim of this study is to evaluate the effectiveness of virtual reality exposure therapy in the management of body dysmorphic disorder in patients with anorexia nervosa, compared to the traditionally proposed body approach in psychomotor therapy.

Eligibility criteria:
inclusion criteria : * female adolescents aged 13 to 18 * with a diagnosis of anorexia nervosa of all types (including purgative and hyperphagic) according to the dsm-v * french as first language * agreed to participate in the study * parental authority holders accepting her participation in the study * affiliated to a social security system patients will not be included in the study: * with a somatic severity criterion: * total aphagia * body mass index (bmi) \< 14kg/m² for those over 17 years of age, bmi \< 13.2kg/m² for those aged 15-16 and bmi \< 12.7kg/m² for those aged 13-14. * confusion * bradycardia \<40/min, tachycardia * blood pressure \< 80/50mmhg * hypothermia \<35.5°c * severe metabolic disorders: hypokalemia \ 150 mmol/l, hypophosphoremia \< 0.5 mmol/l * acetonuria, hypoglycemia \< 0.6g/l * creatinine elevation \> 100micromol/l * cytolysis \> 4n * leuconeutropenia \<1000/mm3 * thrombocytopenia \<6000000/mm3 * suicide attempt in the last month before inclusion * receiving benzodiazepine treatment outside the prescription limits. * psychotic patients or patients with psychoactive substance addiction according to mini kid criteria (sheehan dv et al. reliability and validity of the mini international neuropsychiatric interview for children and adolescents (mini kid). j clin psychiatry 2010;71(3):313-326).

Keywords: anorexia nervosa female adolescents body dysmorphic disorder virtual reality exposure therapy
study of immune modulatory drugs and other treatments in covid-19 patients: sarilumab, azithromycin, hydroxychloroquine trial - corimuno-19 - viro

Conditions: COVID19; SARS-CoV-2 Infection

Summary: the overall objective of the study is to determine the therapeutic effect and tolerance of sarilumab in combination with azithromycin and hydroxychloroquine, compared to sarilumab only, patients with moderate, severe pneumonia associated with coronavirus disease 2019 (covid-19). sarilumab is a human igg1 monoclonal antibody that binds specifically to both soluble and membrane-bound il-6rs (sil-6rα and mil-6rα) and has been shown to inhibit il-6-mediated signaling through these receptors. the study has a cohort multiple randomized controlled trials (cmrct) design. randomization will occur prior to offering investigational treatments administration to patients enrolled in the corimuno-19 cohort (nct04324047). sarilumab+azithromycin+hydroxychloroquine, or sarilumab only will be administered to consenting adult patients hospitalized with covid-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation. all patients will receive standard of care along with randomized investigational treatments. outcomes of included patients will be compared between groups as well as with outcomes of patients in the corimuno-19 cohort treated with other immune modulators or standard of care.


Eligibility criteria:
inclusion criteria: * patients included in the corimuno-19 cohort (nct04324047) * covid-19 cases not requiring icu at admission with moderate or severe pneumopathy according to the who criteria of severity of covid pneumopathy: * moderate cases: cases meeting all of the following criteria: \[showing fever and respiratory symptoms with radiological findings of pneumonia\] and \[requiring between 3l/min and 5l/min of oxygen to maintain spo2\>97%\] or * severe cases: cases meeting any of the following criteria: \[respiratory distress ( ≥ 30 breaths/ min)\] or \[oxygen saturation≤93% at rest in ambient air; or oxygen saturation ≤97 % with o2 \> 5l/min\] or \[pao2/fio2 ≤ 300mmhg\] exclusion criteria: 1. patients with exclusion criteria to the corimuno-19 cohort. 2. respiratory failure requiring non invasive or mechanical ventilation 3. patients requiring intensive care 4. do-not-resuscitate order (dnr order) 5. known hypersensitivity to sarilumab or to any of their excipients. 6. known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, g6pd deficiency and qt prolongation 7. known contra-indication to azithromycin: including hypersensitivity/allergy and qt prolongation 8. pregnancy or breastfeeding 9. current documented bacterial infection. 10. patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n
the intravitreal autologous platelet concentrate injection as an adjunct of vitrectomy for the treatment of refractory macular holes

Conditions: Macular Hole With High Myopia (Spherical Equivalent ≤ -6.0 Diopters) or,; Large Size Macular Hole (Diameter > 600 Microns) or; Recurred or Failed Macular Hole From Previous Surgery; or Chronic Macular Hole (Symptom Duration > 6 Months)

Summary: the purpose of this study is to determine the effectiveness of intravitreal autologous platelet concentrate (apc) injection during the surgery for refractory macular holes.


Eligibility criteria:
inclusion criteria: * macular hole with any of following condition * high myopia (spherical equivalent ≤ -6.0 diopters) * large size macular hole (diameter \> 600 microns) * recurred or failed macular hole from previous surgery * chronic macular hole (symptom duration \> 6 months) exclusion criteria: * systemic infection * hematologic disease * severe maculopathy including severe diabetic retinopathy, advanced age-related macular degeneration
calcineurin inhibitor-free immunosuppression in renal transplant recipients at low immunogenic risk

Conditions: Renal Transplant Recipients

Summary: to compare renal function (51cr-edta clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 dr mis-match, receiving immunosuppressive therapy with a) zenapax® (5 doses), cellcept® (1.5 g bid., aiming for tdm for total trough concentrations of 2-6 mg/l) and prednisolone or b) sandimmun neoral® (full dose), cellcept® (1.0 g bid.) and prednisolone.

primary objective to compare renal function (51cr-edta clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 dr mis-match, receiving immunosuppressive therapy with a) zenapax® (5 doses), cellcept® (1.5 g bid., aiming for tdm for total trough concentrations of 2-6 mg/l) and prednisolone or b) sandimmun neoral® (full dose), cellcept® (1.0 g bid.) and prednisolone. secondary objectives to compare the two treatment groups with regard to: patient and graft survival (12 months), biopsy-proven and presumptive rejection episodes (3 and 12 months), posttransplant (12 months) incidence and severity of hypertension, hyperlipidemia, glucose intolerance, incidence of infection and tolerability and "success rate" of tdm guided cellcept® dosing in a calcineurin inhibitor-free immunosuppressive protocol over 12 months.

Eligibility criteria:
inclusion criteria: * 1. patients of either gender above 18 years of age. 2. patients who are recipients of primary, 0 dr mis-matched renal allografts from cadaveric donors (aged between 10 and 70 years). 3. patients who are single organ recipients (kidney only). 4. if the patients are women of childbearing potential, they must use safe contraceptives. 5. patients not previously treated with zenapax® or simulect®. 6. patients must be capable to understand the information given about the study, including purpose and risks, and they must sign a statement of informed consent in accordance with the helsinki declaration. 7. patients with white blood count greater than 2.5 x 109 /l (iu), platelet count greater than 100 x 109 /l (iu) or haemoglobin greater than 6 g/dl at the time of entry into the study. exclusion criteria: * 1. patients who are recipients of hla-identical renal transplants. 2. pra positive (\>20%) patients at any time the alst 6 months. 3. patients who are unable to stay outside hospital as outpatients for 3 months. 4. patients who are unable to receive oral medication. 5. patients with active peptic ulcer disease. 6. patients with active infection. 7. patients with disorders which might interfere with their ability to absorb oral medication, such as severe diarrhoea or patients with previously diagnosed diabetic gastroenteropathy. 8. patients who are pregnant or nursing mothers. 9. patients with ongoing malignancies, excluding adequately treated skin carcinoma. 10. patients not able to adhere to the investigational immunosuppressive therapy. 11. patients receiving bile-acid sequestants.

Keywords: cadaveric donor calcineurine free
effect of premedication type on preoperative anxiety in children

Conditions: Preoperative Anxiety

Summary: compare the effects of pharmacological and nonpharmacological premedications on preoperative anxiety and mask acceptance after adenotonsillectomy

compare the effects of 0.5 mg/kg oral midazolam, watching film 'suko is being operated' animation film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.wd-yhfu0piu , playing smartphone game ( subway surfers, snail bob or angry birds) on preoperative anxiety by m-ypas in the holding area, in the operating room and while induction of anesthesia. investigators also evaluated mask acceptance by mask acceptance scale investigators also evaluated post operative delirium by paed (postanesthetic emergency delirium) scale at pacu at arrive and every 10 minutes.

Eligibility criteria:
inclusion criteria: * asa 1-2 * elective surgery exclusion criteria: * chronic diseases * development disability * prematurity * neurological diseases * psychoactive medication use * hearing/visual impairment * history of surgery
treatment benefits of berberine supplementation for women with pcos

Conditions: Polycystic Ovary Syndrome

Summary: berberine is a plant alkaloid, reportedly possesses a wide range of pharmacological activities, including anti-obesity and anti-dyslipidemia. berberine is an effective insulin sensitizer and has a comparable activity to met in reducing ir. a large body of evidence suggest that berberine dietary supplementation helps in improvement of symptoms associated with polycystic ovary syndrome (pcos). the purpose of this study is to investigate the treatment benefits of berberine in women with pcos.

berberine (bbr) is an isoquinoline derivative alkaloid that occurs in several plants including oregon grape, barberry, tree turmeric, goldenseal, yellowroot, amur corktree, chinese goldthread, prickly poppy and californian poppy. berberine supplementation has been suggested to improve the symptoms associated with pcos. berberine; reduces insulin resistance lowers blood sugar levels aids in weight loss improves cholesterol levels regulates menstrual cycles reduces inflammation helps restore hormonal balance improves fertility helps combat depression helps fight fatty liver disease improves body composition the present rct is aimed to investigate the effect of berberine on these symptoms associated with pcos.

Eligibility criteria:
inclusion criteria: 1. women aged between 18 and 45 years 2. pcos diagnosis as per the rotterdam criteria (any two of the following features: * irregular periods (allso called oligomenorrea) or no periods (amenorrhea), * higher levels of andregens present in the blood (hyperandrogenism), or physical characteristics of elevated andregen levels such as acne, male-pattern balding, or excess hair growth on face, chin, or body * polycystic ovaries visible on an ultrasound 3. normal, over-weight, and obese class i women (bmi 18.5 - 29.9 kg/m2, bmi cut-off as per the asian criteria) 4. with no desire for pregnancy within 6 months 5. able to give informed written consent exclusion criteria: 1. women who are currently taking or have teken in the last three months medications known to alter insulin physiology, oral contraceptives, ovulation induction drugs, anti- obesity or cholestrol lowering drugs, or any supplement known to interfere with insulin and androgen metabolism such as inositols, curcumin, lipoic acid, cinnamon, gymnemic and other botanical extracts. 2. women undergoing in vitro fertilization treatment. 3. women diagnosed with lateonset congenital adrenal hyperplasia (17-oh progestrone), thyroid disorders, hyperprolactinemia, diabetes mellitus and odst. 4. presence of liver, or renal disease 5. pregnant or lactating or menopause women